Company Long-Term Loans and Borrowings: Agios Pharmaceuticals Inc (AGIO)

Public company logo of Agios Pharmaceuticals Inc (AGIO)

Driven by colossal R&D investments and patent protection, Agios Pharmaceuticals (AGIO) has established a formidable barrier to entry for competitors. The company's revenues are based on the commercialization of innovative drugs for hemolytic anemia. Strong pricing power within the rare disease segment ensures financial stability, while the issuer's long-term liabilities reflect the current metric 0.01, allowing for an assessment of the business's overall resilience.

AGIO Agios Pharmaceuticals Company Long-Term Debts (07/04/2022 - 10/30/2026)

Summary analytical data breakdowns for Agios Pharmaceuticals Inc (AGIO)

- market price and analyst price targets:
Stock Price agios.com|AGIO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Agios Pharmaceuticals|AGIO - Total Company Value
- book capitalization information:
Accounting Value per Share Agios Pharmaceuticals|AGIO - Book Capitalization|Market Capitalization to Book Value Ratio agios.com|AGIO - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Agios Pharmaceuticals|AGIO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Agios Corp|AGIO - Company Aggregate Debts|Debts to Book Value Agios Pharmaceuticals|AGIO - Company Long-Term Liabilities|Amount of Current Liabilities Agios Pharmaceuticals|Quick Ratio agios.com
- earnings and multiples data:
AGIO - Net Profit
Summary company analytics:Agios Pharmaceuticals
Brand item of Agios Pharmaceuticals

This indicator aggregates liabilities with a maturity horizon of over one year, capturing deleveraging rates and the level of debt load within the capital structure. Analyzing the long-term borrowings of Agios Pharmaceuticals (AGIO) allows for an assessment of the company's financial stability as it expands its presence in orphan drug markets, where the capital intensity of commercializing new indications directly determines the debt dynamics on the chart.

Competitor analysis for Agios Pharmaceuticals

Company Long-Term Debts ascendispharma.com ASND|MDGL - Company Long-Term Debt|Company Long-Term Loans and Borrowings CORT (Corcept Therapeutics Inc.)|Rhythm Pharmaceuticals Inc (RYTM) - Company Long-Term Debt|Company Long-Term Liabilities Akero Corp|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com|Company Long-Term Liabilities CRNX (Crinetics)|NAMS (NewAmsterdam Pharma Company) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Soleno SLNO|FOLD - Company Long-Term Liabilities|89bio, Inc. - Company Long-Term Debts|Long-Term Debt structuretx.com|MDXG (MiMedx) - Company Long-Term Liabilities|RZLT: Amount of Long-Term Liabilities|LXRX (Lexicon Pharma) - Company Long-Term Debts|Company Long-Term Debts MBX Corp|Company Long-Term Debts ALT|Company Long-Term Debt AARD (aardvarktherapeutics.com)|Company Long-Term Debt Sagimet Biosciences Inc. SGMT|BioAge Labs (BIOA) - Long-Term Debt|BMEA - Company Long-Term Debt|QNCX: Company Long-Term Debt|GUTS: Company Long-Term Debts|VTVT - Long-Term Debt Volume|Company Long-Term Debt Agape ATP Corp|Pluri Inc (PLUR) - Long-Term Debt Volume|Company Long-Term Debt Synlogic, Inc. (SYBX)|Company Long-Term Liabilities Lipocine Corporation LPCN|Company Long-Term Debts MTNB (Matinas BioPharma Holdings)|Company Long-Term Debts Spruce Biosciences Inc. SPRB|Galecto - Company Long-Term Debts|Long-Term Indebtedness Carmell Corp. (CTCX)|LUMO: Company Long-Term Debts|ONVO - Long-Term Debt Volume|Company Long-Term Debt Radius Recycling, Inc.